What is Leerink Partnrs’ Estimate for ALGN FY2028 Earnings?

Align Technology, Inc. (NASDAQ:ALGN) – Leerink Partnrs cut their FY2028 EPS estimates for Align Technology in a research report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Cherny now anticipates that the medical equipment provider will earn $11.69 per share for the year, down from their previous estimate of $11.71. The consensus estimate for Align Technology’s current full-year earnings is $7.98 per share.

Several other research firms also recently weighed in on ALGN. HSBC downgraded Align Technology from a “buy” rating to a “hold” rating and cut their price target for the stock from $290.00 to $170.00 in a research note on Friday, April 25th. Morgan Stanley cut their target price on shares of Align Technology from $280.00 to $272.00 and set an “overweight” rating for the company in a research report on Thursday, February 6th. Piper Sandler reissued an “overweight” rating and issued a $250.00 price target (up previously from $235.00) on shares of Align Technology in a research report on Thursday, May 1st. Jefferies Financial Group cut their price objective on shares of Align Technology from $285.00 to $260.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Finally, Evercore ISI boosted their target price on shares of Align Technology from $165.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $241.25.

Align Technology Trading Up 0.5 %

Shares of NASDAQ ALGN opened at $181.81 on Friday. The stock has a fifty day simple moving average of $167.96 and a two-hundred day simple moving average of $199.78. Align Technology has a 1-year low of $141.74 and a 1-year high of $283.00. The firm has a market cap of $13.31 billion, a price-to-earnings ratio of 32.41, a price-to-earnings-growth ratio of 2.24 and a beta of 1.68.

Align Technology (NASDAQ:ALGN) last released its earnings results on Wednesday, April 30th. The medical equipment provider reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.13. Align Technology had a net margin of 10.54% and a return on equity of 13.84%. The firm had revenue of $979.26 million during the quarter, compared to the consensus estimate of $977.90 million. During the same period in the prior year, the firm earned $2.14 EPS. The company’s revenue was down 1.8% compared to the same quarter last year.

Institutional Trading of Align Technology

Large investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new stake in Align Technology in the third quarter valued at approximately $78,000. Principal Financial Group Inc. raised its position in shares of Align Technology by 2.7% during the 3rd quarter. Principal Financial Group Inc. now owns 82,020 shares of the medical equipment provider’s stock valued at $20,859,000 after buying an additional 2,168 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Align Technology by 1.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 7,799 shares of the medical equipment provider’s stock worth $1,626,000 after acquiring an additional 91 shares during the last quarter. Czech National Bank grew its position in Align Technology by 6.4% in the fourth quarter. Czech National Bank now owns 15,216 shares of the medical equipment provider’s stock worth $3,173,000 after acquiring an additional 913 shares in the last quarter. Finally, Fulcrum Capital LLC increased its stake in Align Technology by 5.6% in the fourth quarter. Fulcrum Capital LLC now owns 9,212 shares of the medical equipment provider’s stock valued at $1,921,000 after acquiring an additional 489 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

Align Technology announced that its Board of Directors has initiated a stock buyback program on Tuesday, May 6th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 7.9% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.